IS7746A - Meðferðir á þrálátum bólgutengdum afmýlunarfjöltaugakvilla með því að nota beta interferon - Google Patents

Meðferðir á þrálátum bólgutengdum afmýlunarfjöltaugakvilla með því að nota beta interferon

Info

Publication number
IS7746A
IS7746A IS7746A IS7746A IS7746A IS 7746 A IS7746 A IS 7746A IS 7746 A IS7746 A IS 7746A IS 7746 A IS7746 A IS 7746A IS 7746 A IS7746 A IS 7746A
Authority
IS
Iceland
Prior art keywords
treatment
inflammatory demyelinating
beta interferon
persistent inflammatory
multiple neuropathy
Prior art date
Application number
IS7746A
Other languages
English (en)
Icelandic (is)
Inventor
Sandrock Alfred
Original Assignee
Biogen Idec Ma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc. filed Critical Biogen Idec Ma Inc.
Publication of IS7746A publication Critical patent/IS7746A/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IS7746A 2002-09-27 2005-03-15 Meðferðir á þrálátum bólgutengdum afmýlunarfjöltaugakvilla með því að nota beta interferon IS7746A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41430702P 2002-09-27 2002-09-27
PCT/US2003/030532 WO2004028472A2 (en) 2002-09-27 2003-09-26 THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-β

Publications (1)

Publication Number Publication Date
IS7746A true IS7746A (is) 2005-03-15

Family

ID=32043377

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7746A IS7746A (is) 2002-09-27 2005-03-15 Meðferðir á þrálátum bólgutengdum afmýlunarfjöltaugakvilla með því að nota beta interferon

Country Status (21)

Country Link
US (2) US20060182715A1 (https=)
EP (1) EP1575531B9 (https=)
JP (3) JP2006513990A (https=)
KR (1) KR20050059195A (https=)
CN (2) CN102038938A (https=)
AT (1) ATE520412T1 (https=)
AU (1) AU2003277006C1 (https=)
BR (1) BR0314548A (https=)
CA (1) CA2500189A1 (https=)
DK (1) DK1575531T3 (https=)
EA (1) EA009289B1 (https=)
GE (1) GEP20094699B (https=)
IS (1) IS7746A (https=)
MX (1) MXPA05003243A (https=)
NO (1) NO20052059L (https=)
NZ (1) NZ565990A (https=)
PL (1) PL377612A1 (https=)
RS (1) RS20050255A (https=)
UA (1) UA86749C2 (https=)
WO (1) WO2004028472A2 (https=)
ZA (1) ZA200502416B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA86749C2 (en) * 2002-09-27 2009-05-25 Байоджен Айдек Ма Инк. THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-в
TW200633718A (en) * 2004-12-16 2006-10-01 Applied Research Systems Treatment of hepatitis c in the asian population
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
CA2757287C (en) 2009-03-31 2019-09-10 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
JP6153470B2 (ja) * 2011-10-01 2017-06-28 株式会社糖鎖工学研究所 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物
GB201212878D0 (en) 2012-07-20 2012-09-05 Pike Justin Authentication method and system
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
GB201520760D0 (en) 2015-05-27 2016-01-06 Mypinpad Ltd And Licentia Group Ltd Encoding methods and systems
KR102454376B1 (ko) * 2018-07-04 2022-10-17 서울대학교산학협력단 신경손상의 면역세포치료
GB201916441D0 (en) 2019-11-12 2019-12-25 Mypinpad Ltd Computer-implemented system and method
KR20260005778A (ko) * 2024-07-02 2026-01-12 주식회사 카인사이언스 탈수초 질환 치료를 위한 펩타이드 및 IVIg의 병용 요법
KR20260005781A (ko) * 2024-07-02 2026-01-12 주식회사 카인사이언스 만성 염증성 탈수초 다발신경병증에 대한 펩타이드의 투여요법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) * 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
DE3712564A1 (de) * 1987-04-14 1988-11-24 Bioferon Biochem Substanz Verfahren zur konstruktion einer animalen zellinie fuer die herstellung von humanem interferon-beta
DE4128319A1 (de) * 1991-08-27 1993-03-04 Bioferon Biochem Substanz Neues rekombinantes human-ifn-beta, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
IL113280A (en) * 1994-04-12 2004-12-15 Res Dev Foundation A preparation for the treatment of self-immunization diseases with the help of interferon of one type
ZA952797B (en) * 1994-04-12 1996-10-07 Res Dev Foundation Method of treating auto-immune diseases using type one interferons
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
DK1121382T3 (da) * 1998-10-16 2006-11-13 Biogen Idec Inc Interferon-beta-fusionsproteiner og deres anvendelser
DK1656952T3 (da) * 1998-10-16 2014-01-20 Biogen Idec Inc Polyalkylenglycolkonjugater af interferon beta-1A og anvendelser deraf
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
EP2357192A1 (en) * 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6531122B1 (en) * 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
EP1334128A2 (en) * 2000-11-02 2003-08-13 Maxygen Aps New multimeric interferon beta polypeptides
EP2080771A3 (en) * 2001-02-27 2010-01-06 Maxygen Aps New interferon beta-like molecules
AU2002254174A1 (en) * 2001-03-13 2002-09-24 Vical Incorporated Interferon-beta polynucleotide therapy for autoimmune and inflammatory diseases
UA86749C2 (en) * 2002-09-27 2009-05-25 Байоджен Айдек Ма Инк. THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING INTERFERON-в

Also Published As

Publication number Publication date
US20060182715A1 (en) 2006-08-17
MXPA05003243A (es) 2005-09-12
EA009289B1 (ru) 2007-12-28
BR0314548A (pt) 2005-08-09
CN102038938A (zh) 2011-05-04
CN1802170A (zh) 2006-07-12
EP1575531A4 (en) 2008-01-23
ZA200502416B (en) 2005-10-20
CA2500189A1 (en) 2004-04-08
GEP20094699B (en) 2009-06-10
AU2003277006B2 (en) 2009-09-10
NO20052059L (no) 2005-06-27
WO2004028472A3 (en) 2006-01-19
EP1575531A2 (en) 2005-09-21
NO20052059D0 (no) 2005-04-27
AU2003277006C1 (en) 2010-04-01
PL377612A1 (pl) 2006-02-06
AU2003277006A1 (en) 2004-04-19
JP2006513990A (ja) 2006-04-27
NZ565990A (en) 2009-10-30
EP1575531B1 (en) 2011-08-17
KR20050059195A (ko) 2005-06-17
UA86749C2 (en) 2009-05-25
ATE520412T1 (de) 2011-09-15
DK1575531T3 (da) 2011-11-21
EP1575531B9 (en) 2012-02-22
RS20050255A (sr) 2007-08-03
JP2011132248A (ja) 2011-07-07
EA200500545A3 (ru) 2007-04-27
EA200500545A2 (ru) 2005-08-25
WO2004028472A2 (en) 2004-04-08
US20120058083A1 (en) 2012-03-08
JP2007039463A (ja) 2007-02-15

Similar Documents

Publication Publication Date Title
WO2004006756A3 (en) THERAPIES FOR RENAL FAILURE USING INTERFERON-β
NO20070073L (no) Pyrazolderivater, preparater inneholdende disse og metoder for anvendelse derav
IS7746A (is) Meðferðir á þrálátum bólgutengdum afmýlunarfjöltaugakvilla með því að nota beta interferon
DK1377589T3 (da) Oxazolyl-pyrazolderivater som kinaseinhibitorer
NO20052923L (no) Fusjonerte bicykliske nitrogeninneholdende heteroringer
CO5050297A1 (es) Uso de peg-ifn-alfa y ribavirina para el tratamiento de hepatitis c cronica
NO20050497L (no) Anvendelse av CETP inhibitorer og eventuelt HMG COA reduserbare inhibitorer og/eller antihypertensiva
CY1110405T1 (el) Φαρμακευτικες συνθεσεις περιλαμβανοντας δεξτρομεθορφανη και κινιδινη για την αγωγη νευρολογικων διαταραχων
DK1163349T3 (da) Medicinske præparater til behandling af alfa-galactosidase A-mangel
DK1660458T3 (da) 2, 4-pyrimidindiaminer egnede i behandling af neoplastiske sygdomme, in-flammatoriske lidelser og lidelser i immunsystemet.
DK0836485T3 (da) Kaskade-polymer-komplekser, fremgangsmåde til deres fremstilling og farmaceutiske midler indeholdende disse
BRPI0805167A2 (pt) processo para obtenção de albumina humana de alta eficiência para uso em terapia de desintoxicação
ITRM20020105A0 (it) Dispersione poliuretanica con elevata durezza della pellicola, procedimento per la sua preparazione e suo impiego.
BR0014758A (pt) Sistemas e métodos para expressão de proteìna com alto rendimento
DK1651270T3 (da) Medikamenter til inhalation omfattende betamimetika og et anticholinergikum
EA200500764A1 (ru) Фармацевтические композиции и лекарственные формы для трансбуккальной и сублингвальной доставки тизанидина и способы введения тизанидина сублингвально или трансбуккально
WO2007120156A3 (en) Animal models of long qt syndrome and uses thereof
DK1406927T3 (da) Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose
ATE395936T1 (de) Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten
DK1483581T3 (da) Populationsbaserede vurderinger og midler til rangordning af proteiners relative immunogenicitet
ITMI20022411A1 (it) Agenti per la diagnosi e la terapia di tumori che espongono sulla superficie delle cellule proteine alterate.
EA200000163A1 (ru) Противоопухолевое средство
AU2003253894A1 (en) Combination therapies with ftc for the treatment of hepatitis b virus infection
ITMI20021205A1 (it) Uso di proteine per il trattamento della leishmaniosi
ITRM20020130A0 (it) Mezzi diagnostici e terapeutici per la sindrome da ritardo mentale legata al cromosoma x.